Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study

Pharmaceutical company, Qnovia has shared positive results from initial clinical trials of its prescription inhaled smoking cessation therapy.

The drug delivery platform, QN-01, is under evaluation in the US through the US Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) while the Medicines and Healthcare Products Regulatory Agency (MHRA) reviews it in the UK.